Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials

Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials Comments and Opinions Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials Joseph P. Broderick, MD; Opeolu Adeoye, MD; Jordan Elm, PhD ho would have guessed that a scale introduced by Evolution of Statistical Approaches to the mRS WDr John Rankin in 1957 would become the pri- The NINDS (National Institute of Neurologic Diseases and mary outcome scale for almost all acute stroke trials? The Stroke) tissue-type plasminogen activator (tPA) Stroke Trials Rankin Scale was modified to its current form by Charles first demonstrated an efficacious treatment for acute ischemic Warlow and others as part of the UK-TIA (United Kingdom stroke and the mRS was 1 of 4 primary end points for a global Transient Ischaemic Attack) trial in the 1980s, and its end point used in the trials. The proportion of subjects with reproducibility was first examined by van Swieten et al, in an mRS of 0 to 1 (no or minor symptoms but no functional 1988 (Table 1). limitations) was chosen as a primary study end point because There is no perfect stroke outcome scale. Regardless, the it was easily communicable, understandable, and desirable to 7-level, modified Rankin Scale (mRS) has several major http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Stroke Wolters Kluwer Health

Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials

Stroke , Volume 48 (7) – Jul 1, 2017

Loading next page...
 
/lp/wolters-kluwer-health/evolution-of-the-modified-rankin-scale-and-its-use-in-future-stroke-eTVFin0t5S

References (59)

Publisher
Wolters Kluwer Health
Copyright
© 2017 American Heart Association, Inc.
ISSN
0039-2499
eISSN
1524-4628
DOI
10.1161/STROKEAHA.117.017866
pmid
28626052
Publisher site
See Article on Publisher Site

Abstract

Comments and Opinions Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials Joseph P. Broderick, MD; Opeolu Adeoye, MD; Jordan Elm, PhD ho would have guessed that a scale introduced by Evolution of Statistical Approaches to the mRS WDr John Rankin in 1957 would become the pri- The NINDS (National Institute of Neurologic Diseases and mary outcome scale for almost all acute stroke trials? The Stroke) tissue-type plasminogen activator (tPA) Stroke Trials Rankin Scale was modified to its current form by Charles first demonstrated an efficacious treatment for acute ischemic Warlow and others as part of the UK-TIA (United Kingdom stroke and the mRS was 1 of 4 primary end points for a global Transient Ischaemic Attack) trial in the 1980s, and its end point used in the trials. The proportion of subjects with reproducibility was first examined by van Swieten et al, in an mRS of 0 to 1 (no or minor symptoms but no functional 1988 (Table 1). limitations) was chosen as a primary study end point because There is no perfect stroke outcome scale. Regardless, the it was easily communicable, understandable, and desirable to 7-level, modified Rankin Scale (mRS) has several major

Journal

StrokeWolters Kluwer Health

Published: Jul 1, 2017

There are no references for this article.